Ilyang Pharmaceutical Co Ltd
KRX:007570
Intrinsic Value
Il-Yang Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceuticals. [ Read More ]
The intrinsic value of one Ilyang Pharmaceutical Co Ltd stock under the Base Case scenario is 20 013.02 KRW. Compared to the current market price of 13 910 KRW, Ilyang Pharmaceutical Co Ltd is Undervalued by 30%.
Valuation Backtest
Ilyang Pharmaceutical Co Ltd
Run backtest to discover the historical profit from buying and selling Ilyang Pharmaceutical Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Ilyang Pharmaceutical Co Ltd
| Current Assets | 159.1B |
| Cash & Short-Term Investments | 18.9B |
| Receivables | 69B |
| Other Current Assets | 71.2B |
| Non-Current Assets | 300.4B |
| Long-Term Investments | 24.5B |
| PP&E | 198.6B |
| Intangibles | 75.5B |
| Other Non-Current Assets | 1.8B |
| Current Liabilities | 173.7B |
| Accounts Payable | 31.5B |
| Accrued Liabilities | 398.4m |
| Short-Term Debt | 78.2B |
| Other Current Liabilities | 63.5B |
| Non-Current Liabilities | 58.8B |
| Long-Term Debt | 6.3B |
| Other Non-Current Liabilities | 52.5B |
Earnings Waterfall
Ilyang Pharmaceutical Co Ltd
|
Revenue
|
370.5B
KRW
|
|
Cost of Revenue
|
-170.4B
KRW
|
|
Gross Profit
|
200.1B
KRW
|
|
Operating Expenses
|
-175.3B
KRW
|
|
Operating Income
|
24.8B
KRW
|
|
Other Expenses
|
-27.4B
KRW
|
|
Net Income
|
-2.5B
KRW
|
Free Cash Flow Analysis
Ilyang Pharmaceutical Co Ltd
Profitability Score
Profitability Due Diligence
Ilyang Pharmaceutical Co Ltd's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
Score
Ilyang Pharmaceutical Co Ltd's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Ilyang Pharmaceutical Co Ltd's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
Ilyang Pharmaceutical Co Ltd's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Ilyang Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for Ilyang Pharmaceutical Co Ltd is 44 000 KRW .
Shareholder Return
Price
Ilyang Pharmaceutical Co Ltd
| Average Annual Return | 18.75% |
| Standard Deviation of Annual Returns | 107.41% |
| Max Drawdown | -86% |
| Market Capitalization | 250B KRW |
| Shares Outstanding | 18 205 200 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Il-Yang Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceuticals. The company is headquartered in Yongin, Gyeonggi-Do. The firm mainly manufactures and sells pharmaceutical products including prostatitis agents, anti-inflammatory drugs, diabetic agents, gastritis agents, and others. The firm also produces products including nourishing tonics and health supplements, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one Ilyang Pharmaceutical Co Ltd stock under the Base Case scenario is 20 013.02 KRW.
Compared to the current market price of 13 910 KRW, Ilyang Pharmaceutical Co Ltd is Undervalued by 30%.
You don't have any saved screeners yet
